Below are key analyst changes to be aware of in the health care sector. We believe this action could lead to some serious moves in some of these names. Besides earnings, or other major company announcements, analysts upgrades/downgrades can move stocks significantly. This is one of those times where healthcare stocks could move. Here are the key changes:

AmerisourceBergen (NYSE:ABC) initiated with Outperform rating and $105 (12% upside) price target by Evercore ISI.

Arbutus Biopharma (NASDAQ:ABUS) initiated with Buy rating and $10 (82% upside) price target by B. Riley.

AxoGen (NASDAQ:AXGN) initiated with Overweight rating and $37 (29% upside) price target by Cantor Fitzgerald.

Becton, Dickinson and Company (NYSE:BDX) initiated with Overweight rating and $260 (18% upside) price target by Keybanc.

Bruker (NASDAQ:BRKR) initiated with Buy rating and $42 (20% upside) price target by BTIG Research.

Cardinal Health (NYSE:CAH) initiated with Neutral rating and $67 (5% upside) price target by Evercore ISI.

Cerus (NASDAQ:CERS) initiated with Overweight rating and $5 (34% upside) price target by Cantor.

CytomX Therapeutics (NASDAQ:CTMX) initiated with Buy rating and $40 (74% upside) price target by Citigroup.

Quest Diagnostics (NYSE:DGX) initiated with Neutral rating and $103 (4% upside) price target by Evercore ISI.

Boston Scientific (NYSE:BSX) upgraded to Top Pick with a $31 (24% upside) price target by RBC.

CVS Health (NYSE:CVS) upgraded to Overweight with an $88 (17% upside) price target by Morgan Stanley.

AngioDynamics (NASDAQ:ANGO) downgraded to Hold by Craig-Hallum.

Celgene (NASDAQ:CELG) downgraded to Neutral with a $120 (12% upside) price target by BofA/Merrill Lynch.

Please Like And Share Our Content!